Neonatal exposure to genistein ameliorates high-fat diet-induced non-alcoholic steatohepatitis in rats

Chengfei Huang1, Xubai Qiao2 and Bing Dong1*

1State Key Laboratory of Animal Nutrition, China Agricultural University, No. 2 Yuanmingyuan West Road, Beijing 100193, People’s Republic of China
2Pathology Department, Beijing Hospital, Beijing 100730, People’s Republic of China

(Received 6 April 2010 – Revised 8 December 2010 – Accepted 9 December 2010 – First published online 8 March 2011)

Abstract
Non-alcoholic steatohepatitis (NASH) is becoming a prevalent disease in developing countries with no effective therapy. Isoflavones such as genistein have been shown to prevent NASH in a rat model, but the effects of neonatal exposure to genistein on lipid metabolism have been rarely studied. In the present study, three doses of genistein (30, 300 or 1200 mg/rat per d) were injected (subcutaneously) into neonatal male Sprague-Dawley rats at postnatal days 1–5. After weaning, these rats were allowed free access to a high-fat diet for 6 weeks. The results demonstrate that NASH was induced by high fat feeding in the control rats, whereas genistein-treated rats displayed smaller body weight, and lower hepatic inflammation and steatosis. The mid dose of genistein was most effective. Neonatal exposure to genistein also resulted in a lower incidence of apoptotic cells in the liver. Additionally, neonatal genistein-treated rats showed lower hepatic expression of fatty acid synthase and sterol regulatory element-binding protein-1, but higher expression of PPARα, indicative of lower rates of lipid synthesis and higher rates of β-oxidation. These results indicate that neonatal treatment with genistein has a prolonged effect on hepatic lipid metabolism that is maintained post-weaning, offering a potential approach for the prevention of hepatic steatosis and NASH.

Key words: Genistein; Neonates; Lipid metabolism; Steatohepatitis; Steatosis

Non-alcoholic fatty liver disease is becoming increasingly prevalent in developed and developing countries. Although non-alcoholic fatty liver is considered benign, it can progress to non-alcoholic steatohepatitis (NASH), which can then lead to cirrhosis, hepatocellular carcinoma and liver failure11. Clinically, the occurrence of non-alcoholic fatty liver disease/NASH in men is more prevalent than in women2–5. However, to date, there is no effective therapy for NASH4,5, and people are recommended to avoid high-fat foods. An alternative, and more attractive, approach would be the development of protocols to prevent non-alcoholic steatosis.

Isoflavonoids including genistein, the most abundant phyto-oestrogen present in soya, have been reported to have beneficial effects in numerous diseases6,7. Genistein also plays an important role in the regulation of lipid metabolism and has been shown to inhibit high-fat diet (HFD)-induced obesity6,8. Likewise, genistein has been shown to prevent progression to NASH in a rat model11. By enhancing gene expression for enzymes of fatty acid oxidation and inhibiting the expression of those involved in lipogenesis, genistein may lower serum lipid concentrations and fat storage in the body8,9,10,12,13. Thus, it is possible that genistein supplementation may be beneficial in preventing or treating hepatic steatosis. However, prolonged genistein treatment of adult male rats has been reported to cause structural changes in the urethroprostatic complex14 and changes in prostate weight15. In contrast, neonatal exposure to moderate doses of genistein during the first few days after birth does not result in later reproductive changes, in terms of sperm count, sperm motility, testis weight and morphology, in adult rats16,17. We are not aware of any studies that investigated the prolonged effects of neonatal treatment with genistein on the adult response to lipid metabolism. In the present study, we tested the hypothesis that subcutaneous exposure of male rats to genistein during the neonatal period would protect the liver from HFD-induced NASH after weaning. The results indicate that genistein had beneficial effects in preventing HFD-induced NASH through 6 weeks post-weaning.

Abbreviations: FAS, fatty acid synthase; Gen-M, mid-dose genistein; HFD, high-fat diet; NASH, non-alcoholic steatohepatitis; SREBP-1, sterol regulatory element-binding protein-1.

* Corresponding author: Assistant Professor Bing Dong, email dongb@mafic.ac.cn
Experimental methods

Animals

Female Sprague–Dawley rats were purchased from the Beijing Experimental Animal Center, China, at 8 weeks of age. The rats were acclimatised to the laboratory for 2 d before the start of the experiments. Rats were housed individually in a room maintained at 22°C with a constant light–dark cycle (14 h light–10 h dark), and were provided isoflavonoid-free rat chow and water *ad libitum*. The studies were in accordance with the Guidelines for Experimental Animals and approved by the Animal Care and Use Committee of China Agricultural University. Oestrous female rats were cohabitated overnight with a male rat. After copulation was confirmed by vaginal smear and sperm detection, the females were weighed and randomly assigned to four experimental groups. Dams were allowed to deliver naturally, and on the day of birth, pups were weighed, sexed and litters culled to six males. Pups were nursed until weaning at day 21. Genistein was administered by injection (subcutaneously), which bypasses the gastrointestinal tract and thus any modifications that may occur that are related to absorption and/or microbial action. However, injected genistein is reported to produce similar plasma aglycone levels(17) as oral administration, and injection avoids the difficulties in delivery by gavage in neonatal rats. We selected three doses of genistein (30, 300 and 1200 µg/rat per d, equivalent to 4, 40 and 160 mg/kg body weight), with the lower two doses covering doses equivalent to the nutritional exposure of infants to total isoflavones in soya milk(18). The highest dose (1200 µg/rat) was selected since this dose has been reported to down-regulate hormone receptors in the testes of male mice and thus represents potentially toxic amounts of genistein(19). On days 1–5 after birth, the pups received subcutaneous injections of genistein (Sigma Chemical Company, St Louis, MO, USA) in 20 µl of maize oil. Control pups received daily subcutaneous injections of the vehicle (20 µl maize oil). After weaning, pups were allocated to receive a HFD (Table 1) for 6 weeks (9 weeks of age). Pups were weighed weekly, and food intake was monitored twice a week. At 9 weeks of age, food was withdrawn for 12 h overnight. All pups in one litter received the same treatment, and one pup per litter was used for analysis. On the day of the experiment, rats were anaesthetised with sodium pentobarbital (30 mg/kg body weight, intraperitoneally). Blood was drawn by cardiac puncture, and the rats were killed by exsanguination. All rats in the treatment groups were killed for analysis. Samples of the liver were immediately frozen in liquid N2 for mRNA and protein analysis, and samples from different areas of the liver were fixed in buffered formalin for histological examination.

Experimental diet

Dams were provided an American Institute of Nutrition (AIN)-93 rodent diet, containing 20% casein, 0·3% ω1-methionine, 15% maize starch, 50% sucrose, 5% fibre-celfil, 3·5% mineral mixture, 1% vitamin mixture and 0·2% choline bitartrate, *ad libitum* throughout gestation, parturition and lactation. After weaning (21 d), offspring were provided free access to a modified AIN-93 diet (Table 1) of the HFD formula containing 60% energy as fat.

Biochemical analysis

Plasma glucose was determined with a Chemistry Analyzer (RA1000; Bayer Corporation, Leverkusen, Germany) and a Glucose Reagent Kit (Biosino Bio-technology and Science, Inc., Beijing, China). Serum insulin and glucagon were measured using a Rat Insulin ELISA Kit and a Rat Glucagon ELISA Kit (Rapidbio, West Hills, CA, USA). Plasma alanine aminotransferase was measured using a kit from Roche Diagnostics (Mannheim, Germany). Plasma and hepatic cholesterol (Folch(20)-extracted) total cholesterol and TAG concentrations were determined using enzymatic methods (Sigma Chemical Company).

Histological examination

Formalin-fixed and paraffin-embedded liver samples were processed for routine haematoxylin and eosin staining. Liver histology was examined and graded according to the magnitude of steatosis, inflammation and ballooning degeneration of hepatocytes as described previously(4,21). The degree of steatosis was graded 0–4 based on the average percentage of fat-accumulated hepatocytes per field at 200× magnification under haematoxylin and eosin staining (grade: 0 = <5%, 1 = 5–25%, 2 = 26–50%, 3 = 51–75%, 4 = >75%). Inflammation was evaluated by the number of inflammatory cells counted in ten random fields at 200× magnification. Mean values were calculated and are reported as inflammatory cells/mm². Hepatocellular ballooning was evaluated as either negative (absent) or positive (present).

### Table 1. Composition of the experimental diet

<table>
<thead>
<tr>
<th>Component</th>
<th>HFD* (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casein, lactic</td>
<td>200</td>
</tr>
<tr>
<td>l-Cystine</td>
<td>3</td>
</tr>
<tr>
<td>Maize starch</td>
<td>–</td>
</tr>
<tr>
<td>Maltodextrin</td>
<td>125</td>
</tr>
<tr>
<td>Sucrose</td>
<td>68·8</td>
</tr>
<tr>
<td>Cellulose</td>
<td>50</td>
</tr>
<tr>
<td>Maize oil</td>
<td>26</td>
</tr>
<tr>
<td>Lard</td>
<td>245</td>
</tr>
<tr>
<td>Mineral mix</td>
<td>10</td>
</tr>
<tr>
<td>Dicalcium phosphate</td>
<td>13</td>
</tr>
<tr>
<td>Calcium carbonate</td>
<td>5·5</td>
</tr>
<tr>
<td>Potassium citrate</td>
<td>16·5</td>
</tr>
<tr>
<td>Vitamin mix</td>
<td>10</td>
</tr>
<tr>
<td>Choline bitartrate</td>
<td>2</td>
</tr>
<tr>
<td>Total</td>
<td>773·8</td>
</tr>
<tr>
<td>kJ</td>
<td>16985</td>
</tr>
<tr>
<td>kJ/g</td>
<td>21·8</td>
</tr>
</tbody>
</table>

* The HFD of rats is an American Institute of Nutrition (AIN)-93-modified diet with 35% fat (60% fat energy) content.
Hepatocyte apoptosis

Hepatocyte apoptosis was determined in the rat liver by the terminal dUTP nick end labelling assay using a In Situ Cell Death Detection Kit (Roche Diagnostics), according to the manufacturer’s instructions.

Gene expression by real-time PCR

Total RNA was isolated from the liver using an RNAqueous Kit according to the manufacturer’s instructions (Ambion, Foster City, CA, USA) and reverse transcribed using M-MLV RT (Invitrogen, Carlsbad, CA, USA). The primers for complementary DNA amplification of fatty acid synthase (FAS), sterol regulatory element-binding protein-1c (SREBP-1c), PPARα, TNFα, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase genes and the corresponding annealing temperatures are listed in Table 2. The β-actin sequence was used as the internal control. Quantitative real-time PCR was performed using DNA Engine Opticon-2 (MJ Research, Waltham, MA, USA) and DyNAmo SYBR Green qPCR commercial kits (Finnzymes, Finland). The PCR system consisted of 5·0 μl of complementary DNA, 1·0 μl of SYBR Green qPCR mix, 1·0 μl of primer pairs (25 mmol/l for each primer) in a total volume of 10 μl. All samples were assayed in triplicate. The relative mRNA levels of target genes were determined using the relative standard curve method.

Western blotting

Tissues were weighed and homogenised in ice-cold buffer (20 mM-Tris; 0·1 mM-EDTA; 0·1 % Triton X-100; 250 mM-sucrose; protease inhibitor mixture, 50 μl/5 ml; pH 7·6). After centrifugation at 10 000 g for 30 min, supernatants were sampled, and protein (50 μg) was diluted in Laemmli sample buffer (23) and resolved on 10 % (w/v) SDS-polyacrylamide gels. Proteins were electrophoretically transferred to a polyvinylidene fluoride membrane (Amersham International, Amersham, Bucks, UK), and membranes were blocked overnight at 4 °C in Tris-buffered saline (pH 7·6) containing 5 % (w/v) SDS-polyacrylamide gels. Proteins were then incubated for 1 h at room temperature in Tris-buffered saline, 0·5 % non-fat dry milk, containing primary antibodies (0·2 μg/ml) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), washed twice at room temperature for 15 min in Tris-buffered saline, and incubated for 1h at room temperature in Tris-buffered saline, 0·5 % non-fat dried milk, with a 1:2000 dilution of secondary antibody conjugated with horseradish peroxidase (Amersham).

Statistical analysis

All pups in a litter received the same treatments, and one pup per litter was taken for analysis. Results are presented as means with their standard errors, where n indicates the number of litters, and analysed using one-way ANOVA followed by Tukey’s multiple comparison test (SAS, version 6; SAS Institute, Cary, NC, USA). Differences were considered significant at P<0·05.

Results

Body and liver weight

From 5 to 9 weeks (termination of the experiment) after birth, the pups that had received genistein were 15 % lighter compared with the control pups (Fig. 1(A)). There were no differences in body weight among the groups that had received genistein. Similarly, food intake did not differ among any of the groups (results not shown). However, the relative liver weight at 9 weeks was significantly lower in the genistein-treated pups than in control pups. The mid-dose genistein (Gen-M) pups had the smallest livers (Fig. 1(B)).

Liver histology and steatosis

In control pups, the HFD induced an accumulation of fat droplets and infiltration of inflammatory cells into the liver (Fig. 2(A)). This steatosis was characterised by mixed macrovesicular and microvesicular steatosis accompanied by inflammatory cells and ballooning degeneration of hepatocytes. Neonatal exposure to genistein prevented some of the hepatic fat accumulation and inflammation at all three doses (Fig. 2(B)–(D)). The Gen-M treatment displayed the lowest steatosis and inflammatory cell infiltration, together with no evidence of ballooning degeneration of hepatocytes. Again, the Gen-M group presented with the lowest steatosis, hepatic inflammation and ballooning degeneration of hepatocytes (Table 3).

Table 2. Primers used in real-time PCR

<table>
<thead>
<tr>
<th>Genes</th>
<th>Forward primers (5′ → 3′)</th>
<th>Reverse primers (5′ → 3′)</th>
<th>Annealing temperature (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FAS</td>
<td>tcttggaacgctagtggtga</td>
<td>ggaatgtatcatcttggac</td>
<td>60</td>
</tr>
<tr>
<td>SREBP-1c</td>
<td>cgctacgctgctctctca</td>
<td>cactctgacaggctggggt</td>
<td>62</td>
</tr>
<tr>
<td>PPARα</td>
<td>aggttatccagcgtttggtg</td>
<td>cgttgacgctgctctctg</td>
<td>62</td>
</tr>
<tr>
<td>TNFα</td>
<td>acatctcccccaggaaagga</td>
<td>cgcacgacagcaggttctta</td>
<td>59</td>
</tr>
<tr>
<td>PEPCK</td>
<td>gcagcagcagctgttcaag</td>
<td>tccctagctctctctgctgc</td>
<td>64</td>
</tr>
<tr>
<td>G-6-Pase</td>
<td>gaagcgaaggctgtggtgttga</td>
<td>tgcagctctgtcgcgtcagctg</td>
<td>60</td>
</tr>
<tr>
<td>β-Actin</td>
<td>aaccaccgccggtctgac</td>
<td>atgtaacgacaggtttcgc</td>
<td>62</td>
</tr>
</tbody>
</table>

FAS, fatty acid synthase; SREBP-1c, sterol regulatory element-binding protein-1c; PEPCK, phosphoenolpyruvate carboxykinase; G-6-Pase, glucose-6-phosphatase.
Control pups fed the HFD showed a higher incidence of hepatocyte apoptosis compared with pups fed a low-fat diet. HFD-induced hepatocyte apoptosis was prevented by neonatal exposure to genistein (Fig. 3). The number of apoptotic cells (per 400 $\times$ field) was $4.3 \pm 0.4$, $2.6 \pm 0.3$, $1.5 \pm 0.2$ and $3.8 \pm 0.4$ for the control and low-, mid- and high-dose genistein-treated pups, respectively.

**Plasma biochemistry**

Plasma glucose concentrations did not differ between the groups, but the plasma insulin concentration was lower, and that of glucagon was higher, in the HFD-fed genistein-treated pups than in the HFD-fed control pups (Table 4). Genistein-treated pups also had less plasma alanine aminotransferase activity than the control pups (Table 4), with the Gen-M group showing the lowest (by 25.2% compared with the control group) levels. Plasma lipid levels were also decreased (Table 4).

**Hepatic gene expression**

The expression of the gluconeogenic genes, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase, was not significantly different in any of the groups (Fig. 4(A) and (B)). FAS and SREBP-1c are key factors of lipogenesis, and their expression was lower in the genistein-treated groups.
than in the control high-fat group. Again, the Gen-M treatment showed the largest difference from the control group (Fig. 4(A) and (B)). The expression of PPARα, a key regulator of fatty acid oxidation, was higher in pups that received neonatal genistein than in the control pups. Similarly, the expression of carnitine palmitoyltransferase 1, a target of PPARα, was also higher in genistein-treated pups. Tissue inflammation, as characterised by the expression of TNFα, was lowest in the low and mid doses of genistein treatment, with no effect of the high-dose genistein treatment when compared with the control group. In all cases, protein expression, as determined by Western blotting, paralleled the mRNA abundance results (Fig. 4(B)), indicating functional changes in the expression of these genes.

Discussion

Prolonged intake of a HFD is associated with accumulation of liver TAG, inflammatory status and alterations in lipid metabolism-related gene expression that ultimately leads to the development of NASH(24,25). Soyabean genistein has been proposed as a treatment for NASH(26–28). The present study suggests that neonatal treatment with genistein has the potential to prevent hepatic steatosis in rats fed HFD post-weaning. Neonatal (days 1–5) exposure to genistein resulted in lower indices of NASH in rats fed a HFD for 9 weeks. After 6 weeks of HFD treatment, control rats developed symptoms typical of NASH, while rats that were neonatally exposed to genistein displayed significant amelioration of such indices, including lower inflammation and hepatic lipid accumulation, in all three treatment groups.

In previous studies, three doses of genistein have been selected(19,29), which span nutritionally relevant and toxicological amounts of genistein exposure in experimental animals, or in human infants consuming soya formulas(30,31). Similar doses have been used in genistein toxicology tests(19). The effects of neonatal genistein treatment on the amelioration of NASH progression, lower hepatic inflammation and lipid accumulation, and post-weaning were seen in all groups, but the results were not dose-dependent. The liver of pups that received the mid dose of genistein tended to show higher resistance to the effects of high fat feeding.

Table 3. Summary of histopathological lesions in the livers of high-fat diet-induced genistein-treated rats
(Mean values with their standard errors, n 6)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Steatosis† (grade)</th>
<th>Inflammatory cells‡ (per mm²)</th>
<th>Ballooning degeneration of hepatocytes§</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>3.8 ± 0.2</td>
<td>15.6 ± 3.8</td>
<td>+</td>
</tr>
<tr>
<td>Gen-L</td>
<td>2.1 ± 0.1</td>
<td>4.1 ± 1.2</td>
<td>–</td>
</tr>
<tr>
<td>Gen-M</td>
<td>0.7 ± 0.1</td>
<td>1.6 ± 0.1</td>
<td>–</td>
</tr>
<tr>
<td>Gen-H</td>
<td>2.7 ± 0.2</td>
<td>7.8 ± 1.4</td>
<td>+</td>
</tr>
</tbody>
</table>

Control, maize oil-treated rats; Gen-L, low-dose (30 μg/d) genistein; Gen-M, mid-dose (300 μg/d) genistein; Gen-H, high-dose (1200 μg/d) genistein.

† These values are the average grade of steatosis. Grades 0–4 are average percentage of fat-accumulated hepatocytes per field at 200 x magnification under haematoxylin and eosin staining (grade: 0 = <5%, 1 = 5–25%, 2 = 26–50%, 3 = 51–75%, 4 = >75%).

‡ Inflammation was evaluated by the number of inflammatory cells counted in ten random fields at 200 x magnification. The mean of these numbers was calculated and expressed as inflammatory cells/mm².

§ Hepatocellular ballooning degeneration was evaluated as either negative (absent) or positive (present).

Fig. 3. Cell apoptosis in the liver of rats neonatally treated with genistein and fed a high-fat diet for 6 weeks. (A) Terminal dUTP nick end labelling (TUNEL)-positive apoptotic hepatocytes were quantified from twenty randomly selected fields at 400 x magnification. (B) A representative TUNEL staining is shown. Values are means, with standard errors represented by vertical bars (n 20). * Mean values were significantly different from those of the control (P< 0.05). Ctrl, maize oil-treated group; Gen-L, low-dose genistein-treated group; Gen-M, mid-dose genistein-treated group; Gen-H, high-dose genistein-treated group.
with both the low- and high-dose genistein-treated pups showing milder effects. Although the reason for this pattern is not clear, it is possible that the high dose of genistein could have damaged hepatocytes, as this dose has been reported to damage other cell types (19).

As a phyto-oestrogen, genistein has frequently been studied in relation to the disturbance of reproductive functions (32–34) and thus neonatal exposure raises some concerns regarding later sexual development (16,35–38). However, studies of neonatal exposure have yielded inconsistent results (19,29,35–41). In some studies, genistein treatment in dams from gestation to lactation resulted in male offspring reproductive deficiency with decreased testosterone levels (37,38,42), but this morphological deficiency has been reported to be recovered in later life in some studies, and some studies have not found any such differences (35,39–41). These variable results may be due to differences in strains, genistein dosage, treatment period or route of delivery (injection or oral administration) (19,29,35,39). In the present study, we did not observe any differences in testis morphology (data not shown), which suggests that neonatal pretreatment with a safe dose of genistein may be beneficial in the prevention of hepatic steatosis and NASH later in life.

Pharmacokinetic studies of orally administered genistein, in animals (43) and human subjects (44) have revealed that plasma genistein concentrations quickly drop to residual levels within 12–24 h. Similarly, subcutaneously injected genistein results in a fall in plasma-conjugated and aglycone genistein from 3 to 1 mmol/l in 20 h in male mice (17). Thus, the protective effects of neonatally administered genistein, seen at 9 weeks of age, were not due to residual genistein but were due to a persistent effect in the body. This claim is further supported by the finding that there were no differences in liver morphology, or plasma aspartate aminotransferase and alanine aminotransferase activities, in any of our rats at the end of the experiment (results not shown).

Hepatic expressions of FAS, SREBP-1 and PPARα are all reported to be enhanced on high fat feeding, and this underlies both increased lipogenesis and the development of NASH. In the present study, the expression of FAS and SREBP-1 was lower in the genistein-treated animals. This may reflect a protective effect of genistein to prevent the up-regulation of these genes, thereby preventing the development of NASH. In contrast, the expression of PPARα and the down-stream carnitine palmitoyltransferase genes were higher in the genistein-treated animals, again reflective of a protective effect. The genes encoding key hepatic proteins involved in the regulation of lipid metabolism, such as SREBP-1c and PPARα, are known to be potentially programmed by dietary treatment during the gestation and neonatal period. Recent studies have revealed that feeding dams diets comprising different protein and fat can alter hepatic SREBP-1c, PPARα and downstream gene FAS expression (45,46) in adult pups. Perinatal exposure to bisphenol A, an endocrine disruptor, has also been shown to change early adipogenesis (47). We found similar results in the present study that neonatal exposure to genistein changed the expression of lipid metabolism genes such as hepatic SREBP-1c, PPARα and FAS when the pups were later fed a HFD as adults. These results allow us to speculate that as an oestrogenic isoflavone, genistein may play a pivotal role, in that, at a given dose, genistein acts as a weak oestrogenic agonist, but at a higher dose, it may compete with endogenous oestrogen as an antagonist.

The present study showed that a short-term exposure to genistein in the neonatal period maintained hepatic PPARα expression for up to 9 weeks of age. These results indicate a prolonged effect of neonatal exposure to genistein on lipid metabolism that persists well beyond weaning and may offer lifelong benefits in protecting against the deleterious effects of high fat consumption. Although, as noted, our use of subcutaneous injection bypasses the gastrointestinal tract, and the use of genistein does not reflect all the phytochemicals in soya, the procedure was designed to span nutritionally relevant amounts of soya consumption by infants. Although there is considerable controversy regarding the use of soya infant formulae, the present study does illustrate that neonatal genistein alone is effective in ameliorating indices of NASH development that are persistent well beyond weaning.

### Table 4. Plasma glucose, insulin, glucagon, alanine aminotransferase (ALT), plasma lipid levels and hepatic lipid levels in neonatal genistein-treated rats

(Mean values with their standard errors, n 6)

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Plasma Glucose (mmol/l)</th>
<th>Glucagon (ng/ml)</th>
<th>ALT (U/l)</th>
<th>Total cholesterol (mg/l)</th>
<th>TAG (mg/l)</th>
<th>Total cholesterol (mg/g)</th>
<th>TAG (mg/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>9-2</td>
<td>0-1</td>
<td>5-1</td>
<td>195-42</td>
<td>169-24</td>
<td>17-9</td>
<td>148-91</td>
</tr>
<tr>
<td>Gen-L, low-dose (30 μg/d) genistein</td>
<td>8-6</td>
<td>0-1</td>
<td>4-5</td>
<td>145-46*</td>
<td>128-7*</td>
<td>16-82</td>
<td>128-43*</td>
</tr>
<tr>
<td>Gen-M, mid-dose (300 μg/d) genistein</td>
<td>8-6</td>
<td>0-1</td>
<td>4-5</td>
<td>125-11*</td>
<td>110-33*</td>
<td>16-82</td>
<td>106-54*</td>
</tr>
<tr>
<td>Gen-H, high-dose (1200 μg/d) genistein</td>
<td>8-7</td>
<td>0-1</td>
<td>4-5</td>
<td>121-55*</td>
<td>110-33*</td>
<td>16-82</td>
<td>121-55*</td>
</tr>
</tbody>
</table>

Control, maize oil-treated rats; Gen-L, low-dose (30 μg/d) genistein; Gen-M, mid-dose (300 μg/d) genistein; Gen-H, high-dose (1200 μg/d) genistein.

Mean values were significantly different for Gen-L, Gen-M and Gen-H from those of the control: * P<0.05, ** P<0.01.
Fig. 4. (A) Gene quantification and (B) Western blot analysis of rat liver fatty acid synthase (FAS), sterol regulatory element-binding protein-1 (SREBP-1c), PPARα, carnitine palmitoyltransferase 1 (CPT1), TNFα, phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G-6-Pase). (A) Values are means of mRNA abundance, with standard errors represented by vertical bars (n = 6). a,b,c Mean values with unlike letters were significantly different (P < 0.05). (B) Representative Western blots of protein expression in liver homogenates from all groups. Protein expression was normalised to β-actin. Values are means, with standard errors represented by vertical bars (n = 6). a,b Mean values with unlike letters were significantly different (P < 0.05). Ctrl, maize oil-treated group; Gen-L, low-dose genistein-treated group; Gen-M, mid-dose genistein-treated group; Gen-H, high-dose genistein-treated group.
Acknowledgements

C. H. conducted the research. X. Q. provided the essential reagents. They both analysed the data. B. D. designed the research and wrote the manuscript. We are grateful to Dr Malcolm Watford for his help with the preparation of the manuscript. The present study was supported by the National Natural Science Foundation of China (no. 30800789). There are no conflicts of interest in the present study.

References


